Common variable immunodeficiency (CVID) is the most prevalent symptomatic type of human primary immunodeficiency diseases (PID). Clinically, CVID is characterized by increased susceptibility to infections and a wide variety of autoimmune and rheumatologic disorders. All patients with CVID registered in Iranian PID Registry (IPIDR) were enrolled in this retrospective cohort study. We investigated the frequency of rheumatologic diseases and its association with immunological and clinical phenotypes in patients with CVID. A total of 227 patients with CVID were enrolled in this study. The prevalence of rheumatologic disorders was 10.1% with a higher frequency in women than men. Most common rheumatologic manifestations were juvenile idiopathic arthritis (JIA) and adult rheumatoid arthritis (RA) followed by juvenile spondyloarthritis (JSpA) and undifferentiated inflammatory arthritis (UIA). Septic arthritis in patients with CVID with a history of RA and JIA was higher than patients without rheumatologic complication. Patients with CVID with a history of autoimmunity (both rheumatologic and non-rheumatologic autoimmunity) had lower regulatory T cells counts in comparison with patients without autoimmune disorders. There was an association between defect in specific antibody responses and negative serologic test results in patients with rheumatologic manifestations. JIA, RA, JSpA and
| INTRODUCTION
Common variable immunodeficiency (CVID) is the most frequent symptomatic type of human primary immunodeficiency diseases (PID). 1 CVID constitutes a large heterogeneous group of patients with antibody deficiencies, and a prevalence of 1:50 000-1:20 000 has been estimated for the disease. 2, 3 However, due to variable presentations of the disease, lack of physician awareness and misdiagnoses in patients with CVID with atypical clinical manifestations, the prevalence of CVID in our country [registered in Iranian PID Registry (IPIDR)] is underestimated (~1:20 000). CVID is characterized by low levels of serum immunoglobulin (Ig), reduced specific antibody response to polysaccharide and/or protein antigens and increased episodes of infections during childhood or young adulthood. 3, 4 Immune dysregulation in patients with CVID results in lymphoproliferation, granulomatous disease, malignancy, allergy and a higher prevalence of inflammatory and autoimmune conditions. [5] [6] [7] The most common autoimmune disorders in CVID are autoimmune cytopenias followed by rheumatologic, dermatologic and endocrine disorders as well as gastrointestinal autoimmune diseases. 1, 5 The association between CVID and rheumatologic diseases has been reported in several studies. 1, 8 Review of the literature indicated that the frequency of rheumatologic diseases in patients with CVID is 5%-13%. [9] [10] [11] The most prevalent rheumatologic diseases seen in patients with CVID are rheumatoid arthritis (RA; with frequency about 2%-3%), juvenile idiopathic arthritis (JIA; 1%-13%), Sj€ ogren's syndrome (SjS; 1%-8%) and systemic lupus erythematosus (SLE; 1%). 6 The pathogenic mechanism of rheumatologic diseases in CVID is not yet recognized. However, increased autoreactive B cell such as CD21 low B cell, autoantibodies, reduced number of regulatory T cells (Tregs) and abnormalities in cytokine production may result in autoimmune conditions and rheumatologic diseases. [12] [13] [14] [15] [16] [17] [18] Moreover, decreased IL-10-producing regulatory B cells (which play an important role in the development of Tregs and peripheral tolerance) have been reported in patients with CVID. However, Barsotti et al 19 identified that the frequency of these cells has no significant correlation with autoimmunity and Tregs in patients with CVID. So far, a few studies have been conducted to evaluate the frequency and clinical manifestations of rheumatologic diseases in CVID, and no similar study has been reported in Iran. In this study, we investigated the frequency of rheumatologic diseases and also evaluated the correlation of clinical presentations and immunological characteristics of rheumatologic diseases in patients with CVID.
| PATIENTS AND METHODS

| Patients
All patients with CVID diagnosis, those were registered in IPIDR 20, 21 
| Methods
We investigated demographic data such as age, gender, age at disease onset, age of diagnosis and delay of diagnosis. Laboratory data were recorded including complete cell blood count (CBC), T-and B cells subsets (was assessed using flow cytometry analysis), serum levels of Igs [was assessed using nephelometry and enzyme-linked immunosorbent assay (ELISA)], autoantibodies [antinuclear antibody (ANA) profile (antibodies to SS-A, SS-B, Sm, SLC-70, PM-Scl, Jo-1, CENP-B, PCNA, RNP, Ro-52, Histones, Rib.P-protein, AMA-M2 and dsDNA(and anticyclic citrullinated peptide (anti-CCP) were determined using ELISA, whereas fluorescent antinuclear antibody test (FANA) and antineutrophil cytoplasmic antibody (cytoplasmic and perinuclear patterns; cANCA and pANCA) were assessed using immunofluorescence method] and rheumatoid factor (RF; was assessed using immunofluorescence techniques). We also evaluated the rheumatologic manifestations of patients with CVID using a uniform questionnaire based on the patients' documented medical histories in the registry system. The patients were defined with rheumatologic complications if the standard diagnostic criteria [for RA, 23 JIA, 24 JSpA, 25 were fulfilled and confirmed by an experienced rheumatologist both at the time of medical record and during the reevaluation of the clinical and complementary paraclinical findings. Undifferentiated inflammatory arthritis (UIA) was a diagnosis of exclusion made in patients with arthritis, which has caused at least 1 clinically swollen joint in the absence of other abnormalities sufficient to meet criteria for a specified alternative diagnosis. 29 The diagnoses of non-rheumatologic autoimmune diseases were performed as previously described. 1 Due to the hypogammaglobulinaemic condition and defect in specific antibody response in patients with CVID, lower limit of positive results of autoantibody levels considered as significant for establishing the diagnosis of autoimmune diseases. 30 
| Statistical analysis
Values were presented as frequency (number and percentage), mean AE standard deviation (SD) and median (interquartile range, IQR), as appropriate. Fisher's exact test and chi-square tests were used for 2 9 2 comparisons of categorical variables, whereas Mann-Whitney U test and Kruskal-Wallis test and the parametric equivalent of them (t tests, and one-way ANOVA) were used to compare numerical variables. Shapiro-Wilk test was used to check the assumption of normality for a variable, and the parametric or nonparametric test was carried out according to this assumption. Statistical analyses were performed using the SPSS software package, version 22 (SPSS Inc., Chicago, IL, USA). A P value < .05 was considered statistically significant.
3 | RESULTS
| Baseline demographic data
A total of 227 patients with CVID (127 male [55.9%] and 100 female [44. 1%]) with a median (IQR) age at diagnosis of 10 (4.0-19.0) years were enrolled in this study. The patients' characteristics are summarized in Table 1 and  Table S1 . Patients were followed up for 3638.8 patientyears with a mean follow-up period of 16.0 AE 10.7 years per patient. The most prevalent first presentation of immunodeficiency in these patients was an infectious disease ( Figure 1 ). Also, 5 patients (2.2%) showed autoimmune complication as the first presentation of the disease which none of them were rheumatologic [including idiopathic thrombocytopenic purpura (ITP), insulin-dependent diabetes mellitus (IDDM), vitiligo, autoimmune haemolytic anaemia (AIHA) and inflammatory bowel disease (IBD)], while 2 patients had septic arthritis as the first presentation.
| Clinical evaluation
In this study, we found the history of autoimmunity in 81 (35.7%) patients with CVID. The most common autoimmune manifestations were gastrointestinal (14.5%), haematological (11.9%) and rheumatologic (10.1%) disorders ( Figure S1 ). Autoimmunity in the endocrine and neurological systems was also reported in 2.6% and 1.8% of patients with CVID, respectively. Among the patients with CVID with autoimmune manifestations, 30.9% had the first episode of autoimmunity prior to the CVID diagnosis, and 13.6% developed autoimmune manifestations concurrently at the time of the CVID diagnosis. Overlapped autoimmune disorders were documented in 10.5% (n = 24) of these patients. Rheumatologic disorders were documented in 23 of 227 patients with CVID during the course of the disease. The co-occurrence of rheumatologic disorders and non-rheumatologic autoimmune disorders was reported in eleven (gastrointestinal in 5, haematological in 4 and endocrine in 2) of 227 patients (4.8%) ( Figure S2 ). The median (IQR) of age at the onset of rheumatologic and non-rheumatologic autoimmunity was 7.0 (4.3-15.5) and 12.0 (3.0-22.0) years, respectively ( Figure S3 ). In patients with rheumatologic manifestations, 34.8% had the diagnosis of rheumatologic manifestations prior to the diagnosis of CVID. The most common rheumatologic manifestations were JIA [(3.1%); oligoarticular in 4 patients, polyarticular in 2 patients and undifferentiated arthritis in 1 patient] and RA (2.2%) followed by juvenile spondyloarthritis (JSpA; 1.8%) and undifferentiated inflammatory arthritis (UIA; 1.8%) in patients with CVID. Of 5 patients with a history of RA, 3 (60%) had the autoimmune cytopenias, whereas, of 4 patients with JSpA, 3 (75%) had a history of autoimmune gastrointestinal disorders. Rheumatologic disorders were more common in females (16%) patients than male (5.5%; P = .009) ( Table 2) .
Pneumonia, otitis media, splenomegaly and history of allergy and asthma were more common in CVID with the rheumatologic disorders than patients without rheumatologic manifestations; however, the differences were not significant (Table 1) . Moreover, history of septic arthritis was higher in patients with CVID with rheumatologic disorders than those without rheumatologic disorders (17.4% vs 7.8%, P = .128); however, the difference was not significant. This history was more highlighted in patients with RA/JIA than those without rheumatologic disorders (25.0% vs 7.8%, P = .042).
To modify the possible confounding effect of general immunodysregulation in the analysis, patients with CVID were divided into 4 groups: 1-without autoimmunity (n = 146), 2-only rheumatologic autoimmunity (n = 12), 3-only non-rheumatologic autoimmunity (n = 58) and 4 -co-occurrence of rheumatologic and non-rheumatologic autoimmunity (n = 11). As illustrated in Table S2 , the sex ratio (M/F) is lower in group 2 and 4 than other groups (P < .01). Although there were no other statistically significant differences, the age of onset of symptom in group 4 was lower than other groups. Moreover, patients in group 1 have a lower frequency of failure to thrive (FTT) and allergy and asthma, than other groups. Pneumonia, otitis media and septic arthritis were higher, while skin infection, splenomegaly, hepatomegaly and malignancy were lower in group 2 than other groups. Meningitis, chronic diarrhoea and FTT had a higher frequency in group 3 than other groups. Patients in group 4 presented a higher frequency of splenomegaly, hepatomegaly, malignancy and allergy and asthma than other groups (Table S2 ).
| Immunological investigations
There was no statistical difference in Ig levels, B-and T cell total counts in patients with CVID with or without rheumatologic disorders. However, patients with CVID with a history of rheumatologic disorders had a higher number of CD4 + and CD8 + T cells counts than patients without rheumatologic disorders ( Table 3 ). As shown in Table S3 , patients with CVID in group 2 (only rheumatologic autoimmunity) and group 3 (only non-rheumatologic autoimmunity) had lower Tregs and higher CD21 low B cell count than patients in group 1 (without autoimmune disorders). Twenty-six (55.3%) of 47 patients with CVID had a defect in specific antibody responses to polysaccharide (pneumococcal vaccines) and protein (tetanus and diphtheria toxoids) antigens. Eight of these patients had rheumatologic manifestations as follow: JIA: 3, JSpA: 2, RA: 1, SjS: 1 and UIA: 1 case. Among them, autoantibodies (ANAs, anti-ds-DNA, RF, anti-CCP, anti-Ro, anti-La, ASCA and We considered first and second cousins marriages as consanguineous relationship in parents with the common ancestor being no more distant than a great-grandparent.
pANCA) associated with the rheumatologic disorders were only detected in 1 case (12.5%) of RA. We found an association between a defect in specific antibody responses and negative serologic test results in patients with CVID with rheumatologic manifestations (P = .033, X 2 =6.42).
| DISCUSSION
Autoimmunity has been reported to be more frequent among patients with CVID. 1, 31 The CVID typically can present in childhood and early adulthood, but the likelihood of autoimmune diseases in patients with CVID increases by age. 6, 32 It has been reported that autoimmunity affects more than 30% (21%-42%) of patients with CVID. 1, 6, 33 Our results showed that 35.7% of patients had a history of autoimmunity, and similar to our previous studies, autoimmune gastrointestinal, haematological and rheumatologic disorders were the most frequent autoimmune complication 5 ; however, the current study was retrospective and so have limitation of this design, because, in our previous cross-sectional study, the frequency of autoimmunity was higher than that current study and 40.3% of patients with CVID had shown autoimmune manifestation. 10 Therefore, autoimmunity may be an integral part of CVID complications. Autoimmune diseases may be the first presentation of CVID, even in cases with no history of severe infections. 6, 32 In the current study, among the patients with CVID with autoimmune manifestations, 30.9% had the first episode of autoimmunity prior to the CVID diagnosis, and 13.6% had developed autoimmune manifestations concurrently at the time of the diagnosis. In our previous study, among the patients with CVID with autoimmune complications, 44.0% had the first episode of autoimmunity prior to the diagnosis of CVID and 20.0% had developed autoimmune symptoms concurrently at the time of the diagnosis of CVID.
5
Rheumatologic manifestations are one of the main categories of autoimmunity in patients with CVID. In the current study, among patients with CVID with rheumatologic manifestations, 34.8% had these complications prior to the diagnosis of CVID. Moreover, rheumatologic disorders have early onset in comparison with other autoimmunities. Therefore, rheumatologic manifestations seem to be one of the first presentations of the CVID. It is critical to clinical immunologist and rheumatologist to be aware of the main manifestations of CVID in order to reduce the delay in diagnostic and establish timely Ig replacement therapy in these patients.
A wide variety of rheumatologic disorders occurs in patients with CVID, similarly, with a higher prevalence in women than men. [34] [35] [36] [37] Although CVID has an equal sex distribution, our results showed that the frequency of rheumatologic diseases is approximately 3 times higher in women than men. Previous studies have shown that patients with CVID are more prone to JIA, SS and SLE. 34, 36, 38 Polyarticular arthritis that resembles RA is also estimated to occur in 1% to 10% of patients with CVID. 35 However, the most common forms of rheumatologic disorders in our study were JIA (3.1%), RA (2.2%), JSpA (1.8%) and UIA (1.8%), when in our previous study of 52 patients with CVID, 7.7% had JIA. 39 Cunningham et al 40 reported that, in a study of 248
American patients with CVID, 1.6% and 2% of the patients had JIA and RA, respectively. Moreover, in a cohort study of 473 CVID subjects, the prevalence of RA was reported to be approximately 3.2%. 41 Contradicting results could be explained by the complexity of the diagnosis in CVID conditions, as well as environmental and genetic factors that influence the incidence of rheumatologic disorders among different populations.
Patients with rheumatologic disorders are at a higher risk for septic arthritis due to their damaged joints. Accordingly, up to 40% of patients with RA have history of septic arthritis. 44, 45 Moreover, more than 25 cases of septic arthritis have been reported in patients with SLE. 46, 47 Consistent with these findings, history of septic arthritis was documented more frequently in our patients with CVID with rheumatologic disorders, and an association between history of septic arthritis and RA/JIA was also detected. Subsequently, treatment with immunosuppressive drugs, particularly corticosteroids (due to inflammatory and autoimmune diseases), may predispose patients with CVID with the rheumatologic complications to septic arthritis. We evaluate B cell subsets in patients with CVID with and without rheumatologic disorders. Our result showed that patients with CVID with rheumatologic disorders have a lower number of na€ ıve B cell and a higher number of transitional and CD21 low B cells in comparison with patients without rheumatologic disorders; however, the differences were not statistically significant. There is no further study examined the B cell subsets in patients with CVID with rheumatologic disorders. However, D€ orner et al 48 patients with a combination of T1D and CVID with serious impairment of antibody production. Moreover, autoantibodies were not detected in these patients at the time of diagnosis or during the course of the disease. Additionally, the histopathology report of the synovial biopsy in patients with CVID often shows few or no B cells and plasma cells, while infiltrated T cell may be composed of CD8 + cells. 34 Therefore, due to decreased Ig synthesis and lack of autoantibodies as well as unusual pattern of biopsy in patient with CVID, a physical examination performed by an experienced rheumatologist and imaging methods such as X-rays and magnetic resonance imaging (MRI) scans are helpful for making the diagnosis and evaluation of rheumatologic disorders. Also, other complementary methods including human leucocyte antigen (HLA) typing, 35 microbial assays, synovial fluid analysis and biopsy 55 can help to the judgement of rheumatologists; however, some of these methods are still not recommended for use in clinical setting and does not confirm the diagnosis.
In conclusion, rheumatologic complications can be the presenting symptom of immunodeficiency prior to the definite diagnosis of CVID, particularly when accompanied by infectious and inflammatory/autoimmune complications. Due to the complexity of the conditions of the CVID, examination by an experienced rheumatologist and more advanced paraclinical investigations play a key role in the diagnosis and management of rheumatologic diseases in these patients. 
